開放隅角緑内障治療薬市場：製品、薬剤クラス別、流通チャネル、エンドユーザー別-2025-2030年の世界予測

開放隅角緑内障治療薬市場は、2023年に86億4,000万米ドルと評価され、2024年には93億5,000万米ドルに達すると予測され、CAGR 8.74％で成長し、2030年には155億3,000万米ドルに達すると予測されています。

開放隅角緑内障治療薬は、不可逆的な視力低下につながる視神経の損傷を防ぐために眼圧を下げることを目的とした治療を指します。この市場には、プロスタグランジンアナログ、β遮断薬、α作動薬、炭酸脱水酵素阻害薬、Rhoキナーゼ阻害薬、併用薬など、さまざまな医療介入が含まれます。これらの治療が必要なのは、緑内障の最も一般的な病態としてこの病気が蔓延していることに起因しており、特に高齢者層では早期診断と効果的な管理が生活の質を維持するために極めて重要です。これらの治療薬は病院、眼科クリニック、研究開発機関などで使用され、継続的な患者の治療と新しい治療法の開発に欠かせないものとなっています。ヘルスケアに対する意識の高まりと高齢化人口の増加が主要な成長促進要因であることに変わりはなく、一方で薬剤製剤の進歩が有効性と患者のコンプライアンスを向上させています。新たなビジネスチャンスは、徐放性ドラッグデリバリーシステムの開発と、最適化された個別化治療レジメンを約束する個別化医療アプローチにあります。イノベーションを加速させるために、製薬企業と研究機関の協力的パートナーシップを推奨します。

しかし、市場には厳しい規制当局の承認、新薬開拓の高コスト、手術やレーザー治療などの代替療法との競合といった制約があります。さらに、無症候性疾患であることや長期間の薬剤使用による副作用のため、患者の服薬アドヒアランスは依然として課題となっています。これらに対処するための取り組みとしては、費用対効果が高く患者に優しい製剤の開発や、コンプライアンスを高めるための患者教育プログラムへの投資などが挙げられます。市場の革新的な強みは、眼圧を下げるだけでなく、視神経を保護する神経保護戦略や、遺伝子治療の選択肢を探ることにあります。競合情勢が進化する中、規制の変化や技術の統合に対応し続けることが、競合情勢における優位性を維持する上で極めて重要になると思われます。

市場力学：急速に進化する開放隅角緑内障治療薬市場における主要市場インサイトの解明

開放隅角緑内障治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の緑内障有病率の上昇
  • 燃焼剤に対する需要の増加
  • 緑内障を検出する診断ツールの改善
• 市場抑制要因
  • 緑内障治療薬のリコール増加
• 市場機会
  • 開放隅角緑内障治療薬の承認拡大
  • 先進的な開放隅角緑内障治療薬のイントロダクションの増加
• 市場の課題
  • 経験豊富な眼科医の不足

ポーターの5つの力：開放隅角緑内障治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：開放隅角緑内障治療薬市場における外部からの影響の把握

外部マクロ環境要因は、開放隅角緑内障治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析開放隅角緑内障治療薬市場における競合情勢の把握

開放隅角緑内障治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス開放隅角緑内障治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、開放隅角緑内障治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨開放隅角緑内障治療薬市場における成功への道筋を描く

開放隅角緑内障治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に緑内障の罹患率が上昇
    • 燃焼薬の需要増加
    • 緑内障を検出するための診断ツールの改善
  • 抑制要因
    • 緑内障治療薬の回収増加
  • 機会
    • 開放隅角緑内障治療薬の承認増加
    • 先進的な開放隅角緑内障治療法のイントロダクション増加
  • 課題
    • 経験豊富な眼科医の不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 開放隅角緑内障治療薬市場：製品別

• 非PGA
• PGA

第7章 開放隅角緑内障治療薬市場薬剤クラス別

• ビマトプロスト
• ラタノプロスト
• トラボプロスト
• ウノプロストン

第8章 開放隅角緑内障治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 開放隅角緑内障治療薬市場：エンドユーザー別

• 外来手術センター
• 病院
• 眼科クリニック

第10章 南北アメリカの開放隅角緑内障治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の開放隅角緑内障治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの開放隅角緑内障治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Alcon Inc.
• Bausch Health Co. Inc.
• D.Western Therapeutics Institute Inc
• EyePoint Pharmaceuticals, Inc.
• Fera Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Iridex Corporation
• Laboratories Sophia
• Merck and Co. Inc.
• Nicox SA
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY NON-PGAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PGAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY UNOPROSTONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 36. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 38. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 58. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 62. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 131. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 147. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 149. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 151. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 153. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 191. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Open-Angle Glaucoma Therapeutics Market was valued at USD 8.64 billion in 2023, expected to reach USD 9.35 billion in 2024, and is projected to grow at a CAGR of 8.74%, to USD 15.53 billion by 2030.

Open-angle glaucoma therapeutics refer to the treatments aimed at lowering intraocular pressure to prevent damage to the optic nerve, which can lead to irreversible vision loss. This market encompasses a variety of medical interventions, including prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, rho kinase inhibitors, and combination drugs. The necessity of these treatments stems from the disease's prevalence as the most common form of glaucoma, particularly affecting older populations where early diagnosis and effective management are crucial to maintaining quality of life. Application settings include hospitals, ophthalmology clinics, and research institutions, where these therapeutics are integral to both ongoing patient care and novel treatment development. Increased healthcare awareness and a growing aging demographic persist as key growth drivers, while advancements in drug formulations enhance efficacy and patient compliance. Emerging opportunities lie in the development of sustained-release drug delivery systems and personalized medicine approaches that promise optimized, individualized treatment regimens. Collaborative partnerships between pharmaceutical companies and research institutes are advised to accelerate innovation.

Yet, the market encounters limitations such as stringent regulatory approvals, high costs of new drug development, and competition from alternative therapies such as surgery or laser treatments. Additionally, patient adherence remains a challenge due to the asymptomatic nature of the disease and side effects of long-term drug use. Efforts to address these include creating cost-effective, patient-friendly formulations and investing in patient education programs to increase compliance. The market's innovative edge lies in targeting neuroprotective strategies that could protect the optic nerve beyond just lowering intraocular pressure, as well as exploring gene therapy options. As the landscape evolves, staying attuned to regulatory changes and technology integration will be pivotal for maintaining a competitive advantage in the open-angle glaucoma therapeutics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Open-Angle Glaucoma Therapeutics Market

The Open-Angle Glaucoma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of glaucoma globally
  • Increasing demand for combustion drugs
  • Improving diagnostic tools to detect glaucoma
• Market Restraints
  • Rising drug recalls for glaucoma treatments
• Market Opportunities
  • Growing approvals for open-angle glaucoma therapies
  • Rising introduction of advanced open-angle glaucoma therapies
• Market Challenges
  • Lack of experienced ophthalmologists

Porter's Five Forces: A Strategic Tool for Navigating the Open-Angle Glaucoma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Open-Angle Glaucoma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Open-Angle Glaucoma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Open-Angle Glaucoma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Open-Angle Glaucoma Therapeutics Market

A detailed market share analysis in the Open-Angle Glaucoma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Open-Angle Glaucoma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Open-Angle Glaucoma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Open-Angle Glaucoma Therapeutics Market

A strategic analysis of the Open-Angle Glaucoma Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Open-Angle Glaucoma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Bausch Health Co. Inc., D.Western Therapeutics Institute Inc, EyePoint Pharmaceuticals, Inc., Fera Pharmaceuticals, Hikma Pharmaceuticals PLC, Iridex Corporation, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Open-Angle Glaucoma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Non-PGAs and PGAs.
• Based on Drug Class, market is studied across Bimatoprost, Latanoprost, Travoprost, and Unoprostone.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on End Users, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of glaucoma globally
    • 5.1.1.2. Increasing demand for combustion drugs
    • 5.1.1.3. Improving diagnostic tools to detect glaucoma
  • 5.1.2. Restraints
    • 5.1.2.1. Rising drug recalls for glaucoma treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing approvals for open-angle glaucoma therapies
    • 5.1.3.2. Rising introduction of advanced open-angle glaucoma therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of experienced ophthalmologists
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Open-Angle Glaucoma Therapeutics Market, by Product

• 6.1. Introduction
• 6.2. Non-PGAs
• 6.3. PGAs

7. Open-Angle Glaucoma Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Bimatoprost
• 7.3. Latanoprost
• 7.4. Travoprost
• 7.5. Unoprostone

8. Open-Angle Glaucoma Therapeutics Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. Open-Angle Glaucoma Therapeutics Market, by End Users

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Hospitals
• 9.4. Ophthalmic Clinics

10. Americas Open-Angle Glaucoma Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Open-Angle Glaucoma Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Open-Angle Glaucoma Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alcon Inc.
• 3. Bausch Health Co. Inc.
• 4. D.Western Therapeutics Institute Inc
• 5. EyePoint Pharmaceuticals, Inc.
• 6. Fera Pharmaceuticals
• 7. Hikma Pharmaceuticals PLC
• 8. Iridex Corporation
• 9. Laboratories Sophia
• 10. Merck and Co. Inc.
• 11. Nicox SA
• 12. Novartis AG
• 13. Pfizer Inc.
• 14. Sun Pharmaceutical Industries Ltd.
• 15. Teva Pharmaceutical Industries Ltd.